GlaxoSmithKline scores a hit in the battle against HIV, tuberculosis
Pharmaceutical giant GlaxoSmithKline (GSK) said last Monday that it was making strides in the fight against HIV and tuberculosis. Its majority-owned healthcare joint venture ViiV recently reported interim results from a study, giving medical specialists reason for optimism. The company’s dolutegravir treatment appears to be a winner – effective, and well tolerated in patients who are already undergoing tuberculosis treatments (rifampin medication).
GSK had a great week last week – up 4% in 5 days
SOURCE: Yahoo Finance
ViiV’s chief scientific and medical officer, John Pottage, made the following statement about the results:
“Tuberculosis remains the leading cause of death among people living with HIV, accounting for around one in three AIDS-related deaths. Concurrent treatment of TB and HIV remains a challenge as it is compounded by drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome.”
The pill uses a single tablet to treat the disease, rather than the usual three thereby reducing the toxicity risk to patients. It was approved by the FDA late last year, and was heralded as a possible game changer in the fight against HIV and AIDS. Speculation remains that it will “shake up” the $22 billion HIV drug market over the coming year.
In the meantime, ViiV’s rival, Gilead, has gained FDA approval for its own new drug treatment. ViiV is suing its competitor, claiming that the treatment “infringes ViiV’s patents on the drug dolutgravir.” If the courts agree, that could be worth $5 billion in royalty sales to 2024.
Dominion holds GSK in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.